Popular Articles
Teeth Whitening Products

Brain Irradiation In Lung Cancer
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.
generic viagra online
DaVita Study Demonstrates Clinical Application Of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
Sysmex America, Inc. announced that a study titled "Day-to-Day, Week-to-Week, and Day-of-the-Week Variations in Tests of Anemia and Iron Status in Hemodialysis Patients" has identified Sysmex"s Reticulocyte Hemoglobin Equivalent (RET-He) parameter result as key input used by physicians to assist in Anemia treatment decisions in ESRD patients on hemodialysis. David Van Wyck, M.D., Vice President of Clinical Affairs at DaVita Inc., and Emeritus Professor of Medicine and Surgery at the University of Arizona College of Medicine, in Tucson et. al followed five hematologic parameters in 30 patients undergoing hemodialysis three times a week. The patients were followed for 12 consecutive treatment days. The parameters studied were Hb, Hct, reticulocyte Hb (RET He or CHr), TSAT and ferritin levels.
News of the day
First Evidence That Weed Killers Improve Nutritional Value Of A Key Food Crop
"Increase in Nutritionally Important Sweet Corn Kernel Carotenoids following Mesotrione and Atrazine Applications"
Public Health

Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results

Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed. GNS and UCSF have utilized REFS(TM) to discover and validate novel mediators of the cell cycle transition, which is a critical determinant of the rate of cancer cell proliferation and tumor growth. These results were presented by UCSF researcher Dr. Rina Gendelman, a post-doctoral fellow in Dr. W. Michael Korn"s laboratory, at the American Association for Cancer Research 2009 meeting on April 18-22 in Denver, during which Dr. Gendelman received an AACR-Susan G. Komen Scholar-in-Training Award. GNS and prominent UCSF investigators Dr. Joe Gray, Dr. Frank McCormick, and Dr. W. Michael Korn will continue the collaboration through a number of additional projects. Dr. Korn, who is an Associate Professor at UCSF, will lead the UCSF-GNS research partnership. The parties will continue with research to elucidate the RAS-MAPK and PI3K cancer pathways, pathways critical for initiation and progression of many cancers, by building models of breast, pancreatic, and esophageal cancer based on data from ongoing research at UCSF using the REFS(TM) platform and simulation of these models. The discoveries from the ongoing research are expected to include potential novel drug targets in those cancer types. "GNS is excited to be working with UCSF, a world-class research and clinical institution, to tackle key current issues in cancer research," said Dr. Iya Khalil, Executive Vice President and co-founder of GNS. "Our collaborative work with UCSF is one of several examples of GNS"s applying our supercomputer-driven REFS(TM) platform to accelerate better treatments for patients with cancer." Gene Network Sciences and The University of California


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):